IMMUNEONCO-B (01541) Rises Over 5% as Core Product IMM01 Expected to Submit pre-BLA Application by Year-End

IMMUNEONCO-B (01541) surged more than 5%. At the time of writing, the stock was up 5.11% to HK$4.94, with a turnover of HK$8.3481 million.

On the news front, on the evening of January 21, IMMUNEONCO announced that it had successfully completed the enrollment of 104 patients for the Phase III clinical trial of IMM01 (Tedaparicep) as a first-line treatment for chronic myelomonocytic leukemia (CMML) by December 31, 2025. The company anticipates completing the enrollment of 132 patients required for an interim analysis by the end of March 2026.

Furthermore, the company plans to submit a pre-BLA application by the end of 2026. Its Ib/II phase study in the field of atherosclerosis will also advance to the proof-of-concept stage.

As of the announcement date, the Board confirmed that the Group's business operations and clinical development remain normal, and there have been no significant adverse changes in the Group's business operations or financial position.

Notably, according to a disclosure on IMMUNEONCO's official WeChat account, recently, a three-person team from the company attended the 44th Annual J.P. Morgan Healthcare Conference. Dr. Tian Wenzhi, the company's Founder, Chairman, CEO, and CSO, provided a comprehensive overview of the company's development status and key project progress at the Biotech Showcase™.

Dr. Tian Wenzhi, along with the company's senior management team, held intensive meetings with more than ten multinational pharmaceutical and biotechnology companies during the conference. Following the event, they have established in-depth communications with multiple potential partners, receiving positive feedback. Substantial progress is anticipated in 2026, injecting new momentum into the globalization of the company's pipeline.